iSpecimen Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ISPC | ADVB | CTE.AX | BIAF | IMDX | 8YY.SI | |
|---|---|---|---|---|---|---|
| Market cap | 2.12M | 3.47M | 59.55M | 3.76M | 86.72M | 41.60M |
| P/E (TTM) | — | — | 30.5 | — | — | — |
| Forward P/E | -1.1 | — | 19.7 | -4.9 | -3.3 | — |
| Price/book | 0.7 | 0.3 | 12.3 | 0.4 | -4.1 | 24.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.70% | −75.17% | +2.52% | −90.20% | −58.86% | +13.64% |
| Today | +6.75% | −4.55% | 0.00% | −8.15% | −3.28% | −4.00% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All ISPC news ›iSpecimen (NASDAQ:ISPC) and 10x Genomics (NASDAQ:TXG) Financial Review
Posted by Michael Walen on Oct 28th, 2026 10x Genomics (NASDAQ:TXG – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses…
iSpecimen Inc. Stock Surges After Announcing Expanded Cancer Biospecimen Offerings
Stock quotes, market indicators and the latest market news. The premarket surge in iSpecimen Inc. (NASDAQ: ISPC) on Thursday caught the attention of many, with the stock leaping 48% to $6.60 at the early morning’s peak. While it moderated…
iSpecimen changes voting rule for reverse split
Votes submitted after October 9, 2026, on Proposals 1, 3, 4 and 5 will be disregarded; the adjournment applies only to Proposal 2. This supplement changes street-name voting: unlike the prior proxy’s stated rule, brokers, banks and…
E.F. Hutton & Co. Appoints Max Condie as Managing Director, Capital Markets
October 20, 2026 13:54 ET | Source: E.F. Hutton & Co. E.F. Hutton & Co. NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a full-service investment bank and broker-dealer headquartered in New York City, today…
Comparing iSpecimen (NASDAQ:ISPC) and Twist Bioscience (NASDAQ:TWST)
Posted by Defense World Staff on Oct 19th, 2026 Twist Bioscience (NASDAQ:TWST – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
DLA Piper Appoints Ryan Iskandar As Partner To Strengthen APAC Finance Practice
DLA Piper appointed Ryan Iskandar as a Partner in its global Finance practice. Based in the firm’s Sydney office, Iskandar brings experience across derivatives, securitization, structured finance, private credit, and fund-linked…
Deal Origination & Investment Specialist – EDF
EDF’s young and dynamic team is motivated towards the collective goal of transforming Malawi’s exporting sector for accelerated economic development. An exciting opportunity has arisen for energetic and innovative individuals to join EDF.…
Sequoia Financial Sells Interprac Financial Planning Pty
TradingView Sequoia Financial Sells Interprac Financial Planning Pty
iSpecimen Shareholders Approve Key Financing and Acquisition Actions
The latest announcement is out from iSpecimen ( (ISPC) ). Spark’s Take on ISPC Stock According to Spark, TipRanks’ AI Analyst, ISPC is a Neutral. The score is driven mainly by very weak financial performance (sharp revenue decline,…
iSpecimen revises reverse split approval standard
Abstentions and shares not voted have no effect on the proposal, and brokers may vote uninstructed street-name shares. The meeting was convened on October 9, 2026, and stockholders voted on Proposals 1, 3, 4 and 5; only Proposal 2 remains…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net3
- pulse2.com2
- defenseworld.net1
- globenewswire.com1
- malawi24.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.